TKK Symphony Acquisition Corporation (TKKS) today announced that it would be extending the expiration of its tender offer to purchase up to 25,000,000 shares at a purchase price of $10.28, for a third time. The tender offer was expected to expire tonight (at 5:00 p.m.), but will now expire at 5:00 p.m. New York City time, on Wednesday, January 8th, 2020. However, since this is the third extension, we can’t rule out the possibility of even further extensions since TKKS’s SPAC deadline does not expire until February 20, 2020.
However, as of 2:00 p.m., New York City time, today, an aggregate of 24,927,104 ordinary shares have been tendered. That leaves just 72,896 shares and a trust value of approximately only $750,000. That’s a challenging number now matter how you slice it.
TKKS now has a little less than four weeks to work on this deal. Let’s see if 2020 is the better year for them.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...